에스트렐라 이뮤노파르마ESLA 주가

[DEF 14A] 주주총회 위임장 — DEF 14A

Estrella Immunopharma Q1 EPS $(0.05) Beats $(0.18) Estimate

Estrella Immunopharma (NASDAQ:ESLA) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.18) by 72.22 percent. This is a 44.44 percent increase over losses of $(0.09) per share

[NT 10-Q] 10-Q 제출 연기 — NOTIFICATION OF LATE FILING

[10-Q] 분기 실적 — QUARTERLY REPORT

[SCHEDULE 13G] SCHEDULE 13G

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

EMERYVILLE, Calif., May 05, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference.

[10-K/A] 10-K/A — AMENDMENT NO. 1 TO FORM 10-K

[4] 내부자 거래

[10-K] 연 실적 — ANNUAL REPORT

[424B3] 424B3 — PROSPECTUS